Top

Published in:

Open Access 01-12-2015 | Research

Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study

Authors: Ruan Yushan, Chen Wenjie, Huang Suning, Dang Yiwu, Zhong Tengfei, Wickramaarachchi Mihiranganee Madushi, Luo Feifei, Zhang Changwen, Wen Xin, Gopaul Roodrajeetsing, Li Zuyun, Chen Gang

Published in: World Journal of Surgical Oncology | Issue 1/2015

Abstract

Background

Previous studies suggested that expression of cyclin-dependent kinase 5 (CDK5) may promote the migration and invasion of human glioma cells. In this study, we aimed to evaluate the clinical value of CDK5 in different grades of glioma in relation to Ki-67 labeling index (LI).

Methods

We firstly assessed by immunohistochemistry the expression of CDK5 in 152 glioma tissues and 16 normal brain tissues and further explored the relationship between CDK5 expression and other clinical features.

Results

The positive ratio of CDK5 in gliomas (57.2 %) was higher than that in normal brain tissues (12.5 %, P = 0.001). Difference of CDK5 expression among four World Health Organization (WHO) grades was statistically significant (P = 0.001). The significant differences of CDK5 expression were also observed between WHO I glioma (34.8 %) and WHO III glioma (62.5 %), as well as WHO IV glioma (82.8 %; P = 0.026, P < 0.001, respectively). Furthermore, Spearman’s rank correlation confirmed that CDK5 was positively correlated with the pathological grade of glioma (r = 0.831, P < 0.001). The CDK5 expression was also positively correlated with Ki-67 LI (r = 0.347, P < 0.001).

Conclusions

The current result suggests that CDK5 may play an essential role in the tumorigenesis and aggressiveness of gliomas.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedCentralPubMedCrossRef

Huse JT, Aldape KD. The evolving role of molecular markers in the diagnosis and management of diffuse glioma. Clin Cancer Res. 2014;20(22):5601–11. doi:10.1158/1078-0432.ccr-14-0831.PubMedCrossRef

Thon N, Eigenbrod S, Grasbon-Frodl EM, Ruiter M, Mehrkens JH, Kreth S, et al. Novel molecular stereotactic biopsy procedures reveal intratumoral homogeneity of loss of heterozygosity of 1p/19q and TP53 mutations in World Health Organization grade II gliomas. J Neuropathol Exp Neurol. 2009;68(11):1219–28. doi:10.1097/NEN.0b013e3181bee1f1.PubMedCrossRef

Chen WW, Balaj L, Liau LM, Samuels ML, Kotsopoulos SK, Maguire CA, et al. BEAMing and droplet digital PCR analysis of mutant IDH1 mRNA in glioma patient serum and cerebrospinal fluid extracellular vesicles. Mol Ther Nucleic Acids. 2013;2, e109. doi:10.1038/mtna.2013.28.PubMedCentralPubMedCrossRef

Choi H, Bang JI, Cheon GJ, Kim YH, Park CK, Park SH, et al. 18F-Fluorodeoxyglucose and 11C-methionine positron emission tomography in relation to methyl-guanine methyltransferase promoter methylation in high-grade gliomas. Nucl Med Commun. 2014. doi:10.1097/mnm.0000000000000236.

Li J, Taich ZJ, Goyal A, Gonda D, Akers J, Adhikari B, et al. Epigenetic suppression of EGFR signaling in G-CIMP+ glioblastomas. Oncotarget. 2014;5(17):7342–56.PubMedCentralPubMed

Castro-Alvarez JF, Uribe-Arias SA, Mejia-Raigosa D, Cardona-Gomez GP. Cyclin-dependent kinase 5, a node protein in diminished tauopathy: a systems biology approach. Front Aging Neurosci. 2014;6:232. doi:10.3389/fnagi.2014.00232.PubMedCentralPubMed

Chow HM, Guo D, Zhou JC, Zhang GY, Li HF, Herrup K. CDK5 activator protein p25 preferentially binds and activates GSK3beta. 2014.

Odemuyiwa SO, Ilarraza R, Davoine F, Logan MR, Shayeganpour A, Wu Y, et al. Cyclin-dependent kinase 5 regulates degranulation in human eosinophils. Immunology. 2014. doi:10.1111/imm.12416.

10.

Demelash A, Rudrabhatla P, Pant HC, Wang X, Amin ND, McWhite CD, et al. Achaete-scute homologue-1 (ASH1) stimulates migration of lung cancer cells through Cdk5/p35 pathway. Mol Biol Cell. 2012;23(15):2856–66. doi:10.1091/mbc.E10-12-1010.PubMedCentralPubMedCrossRef

11.

Feldmann G, Mishra A, Hong SM, Bisht S, Strock CJ, Ball DW, et al. Inhibiting the cyclin-dependent kinase CDK5 blocks pancreatic cancer formation and progression through the suppression of Ras-Ral signaling. Cancer Res. 2010;70(11):4460–9. doi:10.1158/0008-5472.can-09-1107.PubMedCentralPubMedCrossRef

12.

Pozo K, Castro-Rivera E, Tan C, Plattner F, Schwach G, Siegl V, et al. The role of Cdk5 in neuroendocrine thyroid cancer. Cancer Cell. 2013;24(4):499–511. doi:10.1016/j.ccr.2013.08.027.PubMedCrossRef

13.

Liang Q, Li L, Zhang J, Lei Y, Wang L, Liu DX, et al. CDK5 is essential for TGF-beta1-induced epithelial-mesenchymal transition and breast cancer progression. Sci Rep. 2013;3:2932. doi:10.1038/srep02932.PubMedCentralPubMed

14.

Miyamoto Y, Yamauchi J, Chan JR, Okada A, Tomooka Y, Hisanaga S, et al. Cdk5 regulates differentiation of oligodendrocyte precursor cells through the direct phosphorylation of paxillin. J Cell Sci. 2007;120(Pt 24):4355–66. doi:10.1242/jcs.018218.PubMedCrossRef

15.

Liu R, Tian B, Gearing M, Hunter S, Ye K, Mao Z. Cdk5-mediated regulation of the PIKE-A-Akt pathway and glioblastoma cell invasion. Proc Natl Acad Sci U S A. 2008;105(21):7570–5. doi:10.1073/pnas.0712306105.PubMedCentralPubMedCrossRef

16.

Rai A, Tripathi S, Kushwaha R, Singh P, Srivastava P, Sanyal S, et al. CDK5-induced p-PPARgamma (Ser 112) downregulates GFAP via PPREs in developing rat brain: effect of metal mixture and troglitazone in astrocytes. Cell Death Disease. 2014;5, e1033. doi:10.1038/cddis.2013.514.PubMedCentralPubMedCrossRef

17.

Lagace DC, Benavides DR, Kansy JW, Mapelli M, Greengard P, Bibb JA, et al. Cdk5 is essential for adult hippocampal neurogenesis. Proc Natl Acad Sci U S A. 2008;105(47):18567–71. doi:10.1073/pnas.0810137105.PubMedCentralPubMedCrossRef

18.

Qu D, Xu H, Han X, Wang Y, Ouyang C. Expression of CyclinD1 and Ki-67 proteins in gliomas and its clinical significance. Eur Rev Med Pharmacol Sci. 2014;18:516–9.PubMed

19.

Huang S, Chen G. Overexpression of DcR3 and its significance on tumor cell differentiation and proliferation in glioma. 2014;2014:605236. doi:10.1155/2014/605236.

20.

Trabelsi S, Brahim DH, Ladib M, Mama N, Harrabi I, Tlili K, et al. Glioma epidemiology in the central Tunisian population: 1993–2012. Asian Pac J Cancer Prev. 2014;15(20):8753–7.PubMedCrossRef

21.

Gomori E, Pal J, Kovacs B, Doczi T. Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas. Diagn Pathol. 2012;7:8. doi:10.1186/1746-1596-7-8.PubMedCentralPubMedCrossRef

22.

Xu S, Li X, Gong Z, Wang W, Li Y, Nair BC, et al. Proteomic analysis of the human cyclin-dependent kinase family reveals a novel CDK5 complex involved in cell growth and migration. Mol Cell Proteomics. 2014;13(11):2986–3000. doi:10.1074/mcp.M113.036699.PubMedCrossRef

23.

Contreras-Vallejos E, Utreras E, Gonzalez-Billault C. Going out of the brain: non-nervous system physiological and pathological functions of Cdk5. Cell Signal. 2012;24(1):44–52. doi:10.1016/j.cellsig.2011.08.022.PubMedCrossRef

24.

Liu JL, Wang XY, Huang BX, Zhu F, Zhang RG, Wu G. Expression of CDK5/p35 in resected patients with non-small cell lung cancer: relation to prognosis. Med Oncol (Northwood, London, England). 2011;28(3):673–8. doi:10.1007/s12032-010-9510-7.CrossRef

25.

Levacque Z, Rosales JL, Lee KY. Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients. Cell Cycle. 2012;11(21):4093–5. doi:10.4161/cc.21886.PubMedCentralPubMedCrossRef

26.

Sato Y, Taoka M, Sugiyama N, Kubo K, Fuchigami T, Asada A, et al. Regulation of the interaction of disabled-1 with CIN85 by phosphorylation with cyclin-dependent kinase 5. Genes Cells. 2007;12(12):1315–27. doi:10.1111/j.1365-2443.2007.01139.x.PubMedCrossRef

27.

Ajay AK, Upadhyay AK, Singh S, Vijayakumar MV, Kumari R, Pandey V, et al. Cdk5 phosphorylates non-genotoxically overexpressed p53 following inhibition of PP2A to induce cell cycle arrest/apoptosis and inhibits tumor progression. Mol Cancer. 2010;9:204. doi:10.1186/1476-4598-9-204.PubMedCentralPubMedCrossRef

28.

Tripathi BK, Qian X, Mertins P, Wang D, Papageorge AG, Carr SA, et al. CDK5 is a major regulator of the tumor suppressor DLC1. J Cell Biol. 2014;207(5):627–42. doi:10.1083/jcb.201405105.PubMedCentralPubMedCrossRef

29.

Park AY, Shen TL, Chien S, Guan JL. Role of focal adhesion kinase Ser-732 phosphorylation in centrosome function during mitosis. J Biol Chem. 2009;284(14):9418–25. doi:10.1074/jbc.M809040200.PubMedCentralPubMedCrossRef

30.

Tsai LH, Takahashi T, Caviness Jr VS, Harlow E. Activity and expression pattern of cyclin-dependent kinase 5 in the embryonic mouse nervous system. Dev (Cambridge, England). 1993;119(4):1029–40.

31.

Gao C, Negash S, Wang HS, Ledee D, Guo H, Russell P, et al. Cdk5 mediates changes in morphology and promotes apoptosis of astrocytoma cells in response to heat shock. J Cell Sci. 2001;114(Pt 6):1145–53.PubMed

32.

Catania A, Urban S, Yan E, Hao C, Barron G, Allalunis-Turner J. Expression and localization of cyclin-dependent kinase 5 in apoptotic human glioma cells. Neuro-Oncology. 2001;3(2):89–98.PubMedCentralPubMed

33.

Hsu FN, Chen MC, Chiang MC, Lin E, Lee YT, Huang PH, et al. Regulation of androgen receptor and prostate cancer growth by cyclin-dependent kinase 5. J Biol Chem. 2011;286(38):33141–9. doi:10.1074/jbc.M111.252080.PubMedCentralPubMedCrossRef

Title: Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study
Authors: Ruan Yushan
Chen Wenjie
Huang Suning
Dang Yiwu
Zhong Tengfei
Wickramaarachchi Mihiranganee Madushi
Luo Feifei
Zhang Changwen
Wen Xin
Gopaul Roodrajeetsing
Li Zuyun
Chen Gang
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: World Journal of Surgical Oncology / Issue 1/2015
Electronic ISSN: 1477-7819
DOI: https://doi.org/10.1186/s12957-015-0629-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: a case report

Postoperative recurrence of desmoid tumors: clinical and pathological perspectives

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly

Reconstruction of segmental bone defect of long bones after tumor resection by devitalized tumor-bearing bone

Mixed large cell neuroendocrine carcinoma and adenocarcinoma of the gallbladder: a case report and brief review of the literature

Localized primary gastrointestinal diffuse large B cell lymphoma received a surgical approach: an analysis of prognostic factors and comparison of staging systems in 101 patients from a single institution